Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
The decision was driven by results from the Phase III CAPItello-281 trial,
The Committee backed the combination based on results from the CAPItello-281 Phase III trial, marking a key milestone in the regulatory pathway for AstraZeneca’s targeted therapy strategy in prostate cancer
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
Subscribe To Our Newsletter & Stay Updated
